Quarterly ResultApr 30, 2026, 07:07 AM
NVCR Q1 Net Loss $(71.1)M; Revenue +12.3%; Optune Pax FDA Approval
AI Summary
NovoCure Ltd. reported a net loss of $(71.1) million for Q1 2026, significantly wider than the $(34.3) million loss in Q1 2025, despite a 12.3% increase in net revenues to $174.1 million. The increased loss was primarily driven by a $43.4 million share-based compensation expense related to the USFDA approval of Optune Pax for pancreatic cancer on February 11, 2026. The company also noted it did not draw additional tranches from its senior secured credit facility.
Key Highlights
- USFDA approved Optune Pax for pancreatic cancer on February 11, 2026.
- Q1 2026 Net Loss widened to $(71.1) million from $(34.3) million YoY.
- Net Revenues increased 12.3% to $174.1 million in Q1 2026.
- General and administrative expenses surged 91.8% to $85.9 million, including $43.4 million share-based compensation.
- US revenues grew 3.0% to $96.0 million; International markets revenue rose 28.1% to $73.3 million.
- Did not draw Tranche C or D loans from $400 million senior secured credit facility.
- Basic and diluted net loss per share was $(0.62) vs $(0.31) YoY.
- Net cash used in operating activities improved to $(13.5) million from $(35.7) million.